Salicylate, an IKKβ inhibitor, is under clinical trials for the treatment of type 2 diabetes, and its insulin-sensitizing effect is likely due to this inhibitor's broad spectrum of activity [54,68]. This evidence concerns the gene INS and type 2 diabetes mellitus.